Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06126406 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors

StatusRecruiting
PhasePhase 1
Started2023-11-06
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 13, 2023 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2023-11-09
Study Status, Outcome Measures v1
Primary endpoints2 entries, revised
To evaluate the safetyIncidence of CARTreatment-Tassociated cellAdverse preparationsEvents in the treatment of CEA-positive advanced malignancies [Safety and Tolerability]
2023-11-06
Original filing
Chongqing Precision Biotech Co., Ltd
36 trials monitored
See 1 trial at risk
Breast Cancer
5,180 trials monitored
See 256 trials at risk
Lung Cancer
4,033 trials monitored
See 210 trials at risk
Colorectal Cancer
2,904 trials monitored
See 127 trials at risk
and 4 more diseases
This study is a open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CART cell preparations, and to reliminarily observe the study drug in CEA-positive advanced malignant tumors. The pharmacokinetic characteristics of CART cell preparations for the treatment of patients with CEA-positive advanced malignancies were obtained and the recommended dose and infusion schedule.
Trial Details
NCT Number NCT06126406
Lead Sponsor Chongqing Precision Biotech Co., Ltd
Collaborators: First Affiliated Hospital of Wannan Medical College
Conditions Gastric Cancer, Colon Cancer, Rectal Cancer, Breast Cancer, Lung Cancer, Esophagus Cancer, Cholangiocarcinoma, Pancreas Cancer
Enrollment 60 participants
Start Date 2023-11-06
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-11-13